amilia 50 mg
pro.med.cs praha a.s. - amisulprid - 68 - antipsychotica (neuroleptica)
amilia 400 mg
pro.med.cs praha a.s. - amisulprid - 68 - antipsychotica (neuroleptica)
amilia 200 mg
pro.med.cs praha a.s. - amisulprid - 68 - antipsychotica (neuroleptica)
formoterol cipla 12 mikrogramov
cipla europe nv - formoterol - 14 - bronchodilatantia, antiasthmatica
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresíva - pozrite si dokument s informáciami o produkte.
zyclara
viatris healthcare limited - imikvimod - keratosis; keratosis, actinic - antibiotiká a chemoterapeutiká na dermatologické použitie - liek zyclara je indikovaný na lokálnu liečbu klinicky typické, nehyperkeratotických, nehypertropickej, viditeľné alebo hmatateľné aktinickej keratózy plné tváre alebo temena hlavy bez vlasov u imunokompetentných dospelých, keď iné možnosti lokálnej liečby sú kontraindikované alebo menej vhodné.
haloperidol decanoat-richter
gedeon richter plc., maďarsko - haloperidol - 68 - antipsychotica (neuroleptica)
formoterol-ratiopharm 12 µg
ratiopharm gmbh, nemecko - formoterol - 14 - bronchodilatantia, antiasthmatica
aklief
galderma international, francúzsko - trifarotén - 46 - dermatologica
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drogy obštrukčnej choroby dýchacích ciest, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).